Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 33074627!ä!33074627 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 257.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 291.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 291.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 291.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 291.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 291.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 291.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 291.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 324.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 358.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 358.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 358.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 358.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 358.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 358.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacoeconomic+Review+Report:+Glucagon+Nasal+Powder+(Baqsimi):+(Eli+Lilly++Canada+Inc.):+Indication:+For+the+treatment+of+severe+hypoglycemic+reactions++which+may+occur+in+the+management+of+insulin+treated+patients+with+diabetes++mellitus,+when+impaired+consciousness+precludes+oral+carbohydrates-/-CADTH+Common+Drug+Reviews 2020 ; ä (ä): ä Nephropedia Template TP {{tp|p=33074627|t=2020. Pharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli Lilly Canada Inc ): Indication: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates|pdf=|usr=}}{{33074627}} gab.com Text Pharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli Lilly Canada Inc ): Indication: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates JO: Pharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli Lilly Canada Inc.): Indication: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates-/-CADTH Common Drug Reviews http://www.kidney.de/pget.php?&tw=1&pmid=33074627 #FOAvip Glucagon nasal powder (Baqsimi) is indicated for the treatment of severe hypoglycemia (SH) reactions that may occur in the management of insulin-treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates. It is supplied as a single use nasal dosing device containing a 3 mg single dose at a price of $131.60. The recommended dose is one spray in either nostril. According to the clinical expert consulted by CADTH, the treatment is prescribed to patients in preparation for an emergency involving the Health Canada (HC)-indicated SH event. The sponsor submitted a cost-utility analysis (CUA) based on a decision tree comparing the availability of intranasal glucagon with intramuscular (IM) glucagon for a bystander who noticed a patient experiencing the HC-indicated SH event. The sponsor modelled costs and health consequences arising from a single SH event managed with a single glucagon treatment over a one-year time horizon. The SH event was assumed to be witnessed by a bystander (either a caregiver or an acquaintance) who may decide to administer intranasal or IM glucagon in response. Whether glucagon treatment was attempted and was successful determined related events and health care resource use. A range of events of varying severity were captured, including potential resolution of an SH event without health care resource use; SH event resolution requiring emergency medical service (EMS), emergency department (ED) visit, or inpatient admission; and SH event follow-up care. A bystander with access to intranasal was assumed to be twice as likely to attempt administration of intranasal glucagon to the patient experiencing an SH event compared with attempting administration with IM glucagon. The probabilities of a successful full dose administration for intranasal and IM glucagon were based on the sponsor's treatment performance study of caregivers and other bystanders to a simulated SH event. The efficacy of successfully administered intranasal and IM glucagon was assumed to be equivalent, based on the sponsor's claim that noninferior efficacy was demonstrated in the sponsor's IGBC and IGBB studies. Other parameters were based on Canadian sources and were assumed to be the same between the intranasal glucagon and IM glucagon. Mortality and adverse events were not modelled. In the sponsor's base case, intranasal glucagon was associated with 0.001 incremental quality-adjusted life-years (QALYs) and cost savings of $382 compared with IM glucagon. At a willingness-to-pay threshold of $50,000 per QALY, intranasal glucagon had a 67% probability of being cost-effective compared with IM glucagon. Twit Text FOAVip Pharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli Lilly Canada Inc ): Indication: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates????Pharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli Lilly Canada Inc.): Indication: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates-/-CADTH Common Drug Reviews http://www.kidney.de/pget.php?&tw=1&pmid=33074627 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33074627 #FOAvip English Wikipedia <ref>{{Cite pmid|33074627}}</ref> Pharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli Lilly Canada Inc ): Indication: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates #MMPMID33074627 ä Pharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli Lilly Canada Inc.): Indication: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates-/-CADTH Common Drug Reviews 2020[Mar]; ä (ä): ä PMID33074627show ga Glucagon nasal powder (Baqsimi) is indicated for the treatment of severe hypoglycemia (SH) reactions that may occur in the management of insulin-treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates. It is supplied as a single use nasal dosing device containing a 3 mg single dose at a price of $131.60. The recommended dose is one spray in either nostril. According to the clinical expert consulted by CADTH, the treatment is prescribed to patients in preparation for an emergency involving the Health Canada (HC)-indicated SH event. The sponsor submitted a cost-utility analysis (CUA) based on a decision tree comparing the availability of intranasal glucagon with intramuscular (IM) glucagon for a bystander who noticed a patient experiencing the HC-indicated SH event. The sponsor modelled costs and health consequences arising from a single SH event managed with a single glucagon treatment over a one-year time horizon. The SH event was assumed to be witnessed by a bystander (either a caregiver or an acquaintance) who may decide to administer intranasal or IM glucagon in response. Whether glucagon treatment was attempted and was successful determined related events and health care resource use. A range of events of varying severity were captured, including potential resolution of an SH event without health care resource use; SH event resolution requiring emergency medical service (EMS), emergency department (ED) visit, or inpatient admission; and SH event follow-up care. A bystander with access to intranasal was assumed to be twice as likely to attempt administration of intranasal glucagon to the patient experiencing an SH event compared with attempting administration with IM glucagon. The probabilities of a successful full dose administration for intranasal and IM glucagon were based on the sponsor's treatment performance study of caregivers and other bystanders to a simulated SH event. The efficacy of successfully administered intranasal and IM glucagon was assumed to be equivalent, based on the sponsor's claim that noninferior efficacy was demonstrated in the sponsor's IGBC and IGBB studies. Other parameters were based on Canadian sources and were assumed to be the same between the intranasal glucagon and IM glucagon. Mortality and adverse events were not modelled. In the sponsor's base case, intranasal glucagon was associated with 0.001 incremental quality-adjusted life-years (QALYs) and cost savings of $382 compared with IM glucagon. At a willingness-to-pay threshold of $50,000 per QALY, intranasal glucagon had a 67% probability of being cost-effective compared with IM glucagon. äPharmacoeconomic Review Report: Glucagon Nasal Powder (Baqsimi): (Eli (epmc).pdf DeepDyve Pubget Overpricing